(Q39389259)

11 September 2017

title

Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence (English)

1 reference

11 September 2017

1 reference

1 reference

Yi Ling Teo

1

1 reference

11 September 2017

Manit Saetaew

2

1 reference

11 September 2017

Suthan Chanthawong

3

1 reference

11 September 2017

Yoon Sim Yap

4

1 reference

11 September 2017

Eric Chun Yong Chan

5

1 reference

11 September 2017

Han Kiat Ho

6

1 reference

11 September 2017

Alexandre Chan

7

1 reference

11 September 2017

language of work or name

English

0 references

publication date

28 February 2012

1 reference

Breast Cancer Research and Treatment

11 September 2017

published in

1 reference

11 September 2017

volume

133

1 reference

11 September 2017

issue

2

1 reference

11 September 2017

page(s)

703-711

1 reference

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Metabolism considerations for kinase inhibitors in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Diagnosis and Management of Central Nervous System Metastases from Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Drug-related hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

An in vivo and in vitro comparison of CYP gene induction in mice using liver slices and quantitative RT-PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Cell-based models to study hepatic drug metabolism and enzyme induction in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Cell culture model for acetaminophen-induced hepatocyte death in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Role of reactive metabolites in drug-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Enhanced acetaminophen toxicity by activation of the pregnane X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Drug-drug interactions in oncology: why are they important and can they be minimized?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Gastrointestinal toxicities of novel agents in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Causality assessment in drug-induced hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

Recognizing drug-induced liver injury: current problems, possible solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1995-7

10.1007/S10549-012-1995-7

21 January 2018

Identifiers

DOI

1 reference

release_q5l5v7xpm5behp2pinvxifwiwm

11 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/q5l5v7xpm5behp2pinvxifwiwm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference